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Current methods for detection of mutations by polymerase chain reaction (PCR) and sequence analysis frequently
are not able to detect heterozygous large deletions. We report the successful use of a novel approach to identify
such deletions, based on detection of apparent homozygosity of contiguous single-nucleotide polymorphisms (SNPs).
The sequence analysis of genomic DNA PCR products containing all coding exons and flanking introns identified
only a single heterozygous mutation ( tra) in a patient with classic infantile-onset autosomal recessiveIVS18 + 2
glycogen storage disease type II (GSDII). Apparent homozygosity for multiple contiguous SNPs detected by this
sequencing suggested presence of a large deletion as the second mutation; primers flanking the region of homozygous
SNPs permitted identification and characterization by PCR of a large genomic deletion (8.26 kb) extending from
IVS7 to IVS15. The data clearly demonstrate the utility of SNPs as markers for large deletions in autosomal recessive
diseases when only a single mutation is found, thus complementing currently standard DNA PCR sequence methods
for identifying the molecular basis of disease.
Glycogen storage disease type II (GSDII [MIM 232300])
is an autosomal recessive disorder caused by deficiency
of the lysosomal enzyme acid alpha-glucosidase (GAA
[GenBank accession numbers M34424, Y00839, and
NT_024915]) and the subsequent intralysosomal accu-
mulation of glycogen, predominantly in muscle. Clini-
cally, the disorder ranges from an infantile-onset disease,
with involvement of both cardiac and skeletal muscle
and death before the age of 2 years (Pompe disease), to
an adult-onset, slowly progressive disease impairing only
skeletal muscle.
More than 40 different mutations involving single-
nucleotide changes (missense, nonsense, and splice-site
mutations) or small insertions/deletions have been re-
ported (reviewed in Hirschhorn and Reuser 2001).How-
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ever, only two large deletions have been identified in
patients with GSDII (Huie et al. 1994, 1999). The low
frequency of reported large deletions could reflect the
current extensive use and limitations of methods de-
pending on PCR for detection of mutations.
The first reported large deletion in GSDII (extending
from IVS17 to IVS18, and deleting exon 18) was initially
suspected from results of non–PCR-based methods
(analysis of restriction fragment sizes after digestion,
electrophoresis, Southern blotting, hybridization with
radiolabeled probes, and autoradiography) (Martiniuk
et al. 1990). This deletion was then characterized by
cloning and sequence analysis (Huie et al. 1994) and
was found to be very common in Holland and relatively
common in the United States (Kroos et al. 1995; Hirsch-
horn and Huie 1999). More recently, PCR amplification
and sequence analysis of genomic DNA was used to
identify and characterize a large homozygous Alu-me-
diated deletion extending 3′ of the gene (IVS15 to 3′ of
terminal exon 20). However, the identification of this
deletion and its precise boundaries was facilitated by
consanguinity and, therefore, homozygosity for the de-
letion. Presence of the deletion was suggested by the
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Figure 1 A, Splice-site mutation. The tra splice-siteIVS18 2
mutation results in use of a cryptic splice site in exon 18 and deletion
of the terminal 21 nucleotides of exon 18. RT-PCR of mRNA from
the patient’s fibroblasts (using as primers sequence contained in exon
8 and in exon 20 [5′- GACGTCCAGTGGAACGA and 5′-CAGTGCG-
ATCTAGGGAGA]) revealed a single amplification product of appar-
ently correct size of 1.88 kb (not shown). Direct sequence analysis of
the RT-PCR product with an antisense primer located in exon 20
revealed only homogenous sequence indicating lack of detectable nor-
mally spliced mRNA and containing the abnormal splice with deletion
of the terminal 21 nucleotides in exon 18 and splicing to exon 19 on
the allele not bearing the large 8-kb deletion. B, Deletion mutation.
Deletion junction between IVS7 and IVS15 resulting from an 8.26-kb
genomic deletion extending from IVS7–19 to IVS15–17. Sequence
analysis of the smaller than normal product resulting from amplifi-
cation with primers in IVS5 and IVS16 (726 bp vs. 9.027 kb) revealed
the site of the deletion junction, depicted graphically. The deletion
extends from IVS7–19 to IVS15–17); (cagcagacggtgtgccatc).
inability to amplify a series of contiguous exons down-
stream of exon 14 (Huie et al. 1999). Prior knowledge
of the sites of Alu elements in the acid alpha-glucosidase
gene (Martiniuk et al. 1991; R.H., unpublished sequence
analysis) allowed for precise definition of the boundaries
of this large Alu-Alu–mediated deletion (Huie et al.
1999). However, the deletion would have been missed
easily if it had been present in heterozygosity in a non-
consanguineous family. We previously suggested that,
when only one heterozygous mutation is identified by
sequence analysis of all exons and flanking intronic
regions, apparent homozygosity for single-nucleotide
polymorphisms (SNPs) extending over a large region
should raise suspicion of a heterozygous large deletion
(Huie et al. 1999). This hypothesis has now led to the
identification of a novel large intragenic deletion
(IVS7–IVS15), heteroallelic with a previously identified
splice-site mutation ( tra) (Fernandez-HojasIVS18 2
et al. 2002).
The patient, of El Salvadoran heritage, presented at
age 5 mo with hypotonia, cardiomegaly, hepatosplen-
omegaly, developmental delay, and a vacuolar myopa-
thy. The diagnosis of GSDII was confirmed by absence
of acid alpha-glucosidase activity in muscle (0 nmol vs.
normal nmol methylumbelliferyl-a-D-glu-8.13 2.1
coside hydrolyzed/min/g).
PCR amplification of genomic DNA from this pa-
tient and sequencing of all 19 coding exons and the
flanking intronic regions identified only a single het-
erozygous mutation at a splice site ( tra;IVS18 2
also reported in a second patient, of Spanish descent,
with classic infantile GSDII [Fernandez-Hojas et al.
2002]). The additional studies reported herein further
demonstrate that the mutation results in use of a cryp-
tic splice-site mutation in exon 18 (fig. 1A) and splic-
ing out of the terminal 21 nucleotides of exon 18 (nt
2627–2646, ), deleting codons 876–882ATGp 1
(amino acids VIFLARN). Although the translation
frame is retained, splicing out of codons 876–882 deletes
an asparagine (N); the sixth of seven N-linked glyco-
sylation sites (N882) involved in localization of the en-
zyme to lysosomes. Prior in vitro experiments replacing
the asparagine with glutamine and thus disrupting the
AsnXSer/Thr motif required for N-linked glycosylation
were reported to show a deleterious effect at only one
of the sites (N233) (Hermans et al. 1993). By contrast,
in vivo, this is the second case in which a patient with
infantile-onset GSDII has been found to carry a deletion
mutation at one of the seven N-linked asparagine gly-
cosylation sites—del N882 (present report) and del
N470 (Fernandez-Hojas et al. 2002). The deleterious
effects of these two deletions of asparagine at N-linked
glycosylation sites could result in either interferencewith
targeting to lysosomes or an unstable protein. The in-
frame deletion, in theory, predicts retention of acid al-
pha-glucosidase protein or cross-reacting material and
nonproduction of antibody that could interfere with the
efficacy of enzyme-replacement therapy.
The inability to detect a second mutation despite clear
heterozygosity of the splice-site mutation in IVS18, com-
bined with observation of homozygosity for all 14 SNPs
from exon 8 to exon 17, suggested that the second chro-
mosome carried a large deletion that was missed by stan-
dard DNA PCR-based detection methods. Heterozygos-
ity for SNPs in IVS5 and exon 18 suggested approximate
boundaries for a large intragenic deletion. (These SNPs,
their location [for exons, numbers p cDNA from the
start of translation], and the average heterozygosity de-
termined in 15–76 chromosomes are as follows: IVS5
12 g/a [0.49]; 1203 A/G in exon 8 [0.49]; 1374 C/T
in exon 9 [0.18]; IVS9–19 c/g [0.48]; IVS9–7 t/c [0.16];
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IVS10–52 a/c [0.49]; 1581 A/G in exon 11 [0.42]; IVS13
21 g/a [0.08]; IVS14–64 g/a [0.39]; IVS14–5 t/g [0.09];
2065G/A in exon 15 [0.16]; 2133 A/G in exon 15 [0.34];
2338 G/C in exon 17 [0.42]; and 2553 A/G in exon 18
[0.50]) (modified from the summary, table, and diagram
of gene structure in Hirschhorn and Reuser 2001 [except
IVS14–64 g/a, described herein]). PCR amplification
with primers in IVS5 and IVS16, flanking the presumed
deletion, resulted in a smaller than expected product
(0.767 vs. 9.027 kb), consistent with a large deletion
(8.26 kb). Sequence analysis of the smaller-than-ex-
pected fragment identified the deletion junction at
IVS7–19 and IVS15–17 (fig. 1B). Computer analysis did
not reveal any obvious repetitive or homologous se-
quence(s) that would suggest a mechanism for the de-
letion. The 8.26-kb deletion includes the enzyme cata-
lytic site in exon 10–11 and at least one evolutionarily
conserved region in exon 14 (Huie et al. 1998). Analysis
of parental DNA revealed that the large deletion was
paternally inherited, whereas the IVS18 splice-site mu-
tation was maternally inherited.
Use of PCR and automated sequence analysis has al-
lowed for detection of a large spectrum of mutations at
an accelerated rate. However, some mutations, partic-
ularly large deletions, may be missed by these methods.
For example, we previously were able to identify a large
Alu-Alu–mediated deletion only because of consanguin-
ity and homozygosity in the proband, leading to failure
to amplify a series of contiguous exons (Huie et al.
1999). The currently described IVS7–IVS15 deletionwas
suspected after only one clearly heterozygous mutation
was identified, despite complete sequence analysis, and
homozygosity for multiple contiguous SNPs was noted
5′ of the heterozygous mutation. Conversely, large de-
letions on the second allele overlapping the locus of a
detected mutation may be missed because the identified
mutation is erroneously presumed to be homozygous.
This emphasizes the need for confirmation of homozy-
gosity in the proband by identification of the mutation
in both parents.
Although our laboratory has been able to identify
both mutations, in unpublished results, on 100% of the
40 chromosomes studied by these DNA PCR-based
methods, others have reported identification of muta-
tions detected by PCR-based methods in only 29 (69%)
of 42 chromosomes (Laforet et al. 2000) and 17 (77%)
of 22 chromosomes (Ko et al. 1999). These latter results
could reflect technical problems or mutations in the pro-
moter and other noncoding regions, but they could also
reflect high frequency of either the large deletions we
have identified or as yet unidentified deletion(s) in the
two ethnic populations (French and Taiwanese) studied
by these authors.
In summary, large deletions should be considered in
autosomal recessive disorders when one mutation is pre-
sent in heterozygosity but the second mutation is not
detected, despite sequence analysis of all coding exons
and their flanking intronic regions, and multiple contig-
uous SNPs are present in apparent homozygosity. In ad-
dition, when mutations and SNPs are present in appar-
ent homozygosity, despite reports of nonconsanguinity,
a large deletion should ideally be ruled out by studies
of parents, to allow for effective counseling (unless the
mutation is a frequent mutation from a common foun-
der). The same principles could apply to autosomal dom-
inant disorders when there is failure to identify a mu-
tation in an affected individual.
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